Clinical

Only about 10 cases of hypoparathyroidism related to systemic lupus erythematosus (SLE) have been reported, according to researchers who recently described such a case.

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.

A new report finds inflammation scores can predict outcomes among patients receiving immunotherapy for intrahepatic cholangiocarcinoma (ICC).

William B. Miller, Jr, MD, evolutionary biologist, medical doctor, and author explains the importance of cellular research in finding inventive solutions to the growing burden of cancer.

Syma Iqbal, MD, discusses how ESCC and GI cancer treatment pathways may have a myriad of effects on patient quality of life.

A medical expert discusses treating patients with ESCC and GI cancers as recommended by current FDA and NCCN guidelines.

However, the researchers said their findings should not be interpreted as completely refuting the possibility that hydroxychloroquine might be a useful tool in preventing or slowing the development of systemic lupus erythematosus (SLE).

Despite the use of therapies to address the clinical manifestations of myelofibrosis (MF) and essential thrombocythemia (ET), the symptom burdens of these conditions continue to negatively affect patient quality of life (QOL).

Risk for individual hepatobiliary cancers varies from comorbidity to comorbidity, researchers found.

Findings of a recent study suggest that complications of sickle cell disease (SCD) significantly contribute to morbidity and are more prevalent among older patients.

A search of the peer-reviewed literature turned up inconsistent findings on the effectiveness of corticosteroid irrigation for the treatment of chronic rhinosinusitis (CRS) with nasal polyps.

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.

Expert panelists explore challenges impacting care access for patients with MDS.

In the last 2 years, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) have updated their recommendations to integrate guidance for new treatment options.

A Swedish population-based study adds to data suggesting men have a higher risk of lymphoma and likely higher mortality.

Among the challenges are a lack of reliable biomarkers and resistance in some patients who have squamous cell carcinoma (SCC).

Inhaled corticosteroid (ICS) therapy was not the most appropriate treatment for many patients with chronic obstructive pulmonary disease (COPD) in a review of patient records at 2 US primary care clinics.

The question of whether bone erosion is a feature of Jaccoud arthropathy has remained controversial among persons who have systemic lupus erythematosus (SLE).

The study, which assessed changes in circRNA and miRNA after beginning treatment with secukinumab, revealed a prompt change in circRNA abundance upon initiation of treatment and a strong correlation between circRNA and the psoriasis area and severity index.

This study found that the recent change to remove race from the calculation of estimated glomerular filtration rate (eGFR) may incorrectly label potential donors who are Black as having chronic kidney disease (CKD).

The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.

In her final thoughts, Dr Oskouei discusses how patient care may be improved by increased access to biosimilars.

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.

Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo.

The panel discusses emerging treatments for vitiligo and addresses opportunities for payers to support implementation.

CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment.

Syma Iqbal, MD, provides an overview of the KEYNOTE-590 trial and its impact on treatment pathways for ESCC and GI cancers.

Molecular differences may help explain geographic gaps in outcomes.

The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.